This article is for informational and educational purposes only and does not constitute medical advice. Semaglutide and tirzepatide are supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and are not approved by the FDA for human or veterinary use.
Wholesale Peps is not affiliated with, endorsed by, or in any way connected to Novo Nordisk A/S or Eli Lilly and Company. This comparison is compiled from publicly available peer-reviewed literature for educational purposes only.
Semaglutide is a single-target GLP-1 receptor agonist. Tirzepatide is a dual GIP / GLP-1 receptor co-agonist — it activates a second incretin receptor from the same molecule. That extra target is the central difference between the two, and in published clinical trials it is associated with larger average weight and glycemic reductions for tirzepatide. The two have been compared directly in only one trial to date (SURPASS-2), which used the lower 1 mg semaglutide dose.
Semaglutide
- Targets: GLP-1R only
- 31 amino acids · ~4,114 Da
- Half-life ~7 days (weekly)
- STEP 1 weight: ~−14.9%
- Mature CV + kidney outcome data (SELECT, FLOW)
- Brands: Ozempic, Wegovy, Rybelsus
Tirzepatide
- Targets: GIPR + GLP-1R
- 39 amino acids · ~4,814 Da
- Half-life ~5 days (weekly)
- SURMOUNT-1 weight: ~−20.9%
- SURPASS-CVOT: noninferior to dulaglutide (superiority ns)
- Brands: Mounjaro, Zepbound
Weight figures are from separate obesity trials (STEP 1, 68 wk; SURMOUNT-1, 72 wk) and are not a controlled head-to-head. This summary describes published research and is not medical advice.
Semaglutide and tirzepatide are the two most extensively studied injectable incretin compounds in modern metabolic research. Both are once-weekly, albumin-bound acylated peptides that resist DPP-4 cleavage, and both act as glucose-dependent insulin secretagogues. The defining distinction is receptor coverage: semaglutide is a selective full agonist at the GLP-1 receptor (GLP-1R), whereas tirzepatide co-activates both GLP-1R and the GIP receptor (GIPR). Across their pivotal phase 3 programs — STEP and SUSTAIN for semaglutide, SURMOUNT and SURPASS for tirzepatide — tirzepatide reported larger average weight and HbA1c reductions, and the single direct head-to-head trial (SURPASS-2) favored tirzepatide against semaglutide 1 mg. Semaglutide, however, holds the clearer placebo-controlled cardiovascular (SELECT) and dedicated renal (FLOW) outcome evidence. This page compares the two on mechanism, structure, pharmacokinetics, efficacy data, safety, and evidence maturity. All referenced data derive from human clinical trials; in vitro applications of either compound are for receptor pharmacology and mechanistic research only.
1. Semaglutide vs Tirzepatide — Master Comparison Table
The table below summarizes the two compounds across the attributes most often searched. Figures are drawn from the peer-reviewed clinical literature and the compound profiles reviewed in depth on each individual research page. Efficacy values from separate trials are not directly interchangeable; see the section on cross-trial limitations.
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 receptor agonist (monoagonist) | Dual GIP / GLP-1 receptor co-agonist |
| Receptor targets | GLP-1R | GLP-1R + GIPR |
| Developer | Novo Nordisk | Eli Lilly |
| Peptide length | 31 amino acids | 39 amino acids |
| Molecular weight | ~4,114 Da | ~4,814 Da |
| Fatty-acid acylation | C18 diacid (mini-PEG linker) | C20 diacid (γ-Glu spacer) |
| Elimination half-life | ~7 days | ~5 days |
| Typical dosing interval | Once weekly (SC); oral form exists | Once weekly (SC) |
| Pivotal obesity trial weight change | STEP 1: ~−14.9% (2.4 mg, 68 wk) | SURMOUNT-1: ~−20.9% (15 mg, 72 wk) |
| Diabetes HbA1c reduction (Ph 3 range) | ~1.1–1.8 pp (SUSTAIN) | ~1.9–2.6 pp (SURPASS) |
| Cardiovascular outcomes | SELECT: MACE HR 0.80 (established) | SURPASS-CVOT: noninferior to dulaglutide; superiority not significant |
| Kidney outcomes | FLOW: composite HR 0.76 (established) | No dedicated outcomes trial reported yet |
| Predominant adverse events | GI: nausea, diarrhea, vomiting, constipation | GI: nausea, diarrhea, vomiting, constipation |
| Brand equivalents | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| First FDA approval | 2017 (Ozempic, T2D) | 2022 (Mounjaro, T2D) |
2. The Core Difference: One Receptor vs Two
Every downstream contrast between these two compounds traces back to a single design decision. Both molecules are engineered incretin-mimetics that resist enzymatic breakdown and bind serum albumin for a long half-life. The difference is how many incretin receptors each one engages.
Semaglutide is a selective full agonist at the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor that signals through Gs-mediated cyclic AMP (cAMP). GLP-1R activation drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression via hypothalamic and brainstem circuits [10]. This is the well-characterized mechanistic foundation shared across the entire GLP-1 agonist class.
Tirzepatide also activates GLP-1R while adding agonism at the GIP receptor (GIPR) — the receptor for glucose-dependent insulinotropic polypeptide, a second incretin hormone — with receptor pharmacology described as imbalanced and biased in experimental systems. Specifically, studies characterize it as an imbalanced dual agonist (roughly 5-fold greater potency at GIPR than GLP-1R in cAMP assays) and as a biased agonist at GIPR, activating downstream pathways differently from native GIP [4]. Historically, GIPR agonism alone was thought to have limited or even counterproductive effects on body weight; the clinical observation that combined GIPR/GLP-1R co-agonism produces greater weight reduction than GLP-1R agonism alone was unexpected, and the mechanism behind it remains an active research question.
3. Structure & Pharmacokinetics Compared
Both compounds use the same two engineering strategies that define modern long-acting incretins: an alpha-aminoisobutyric acid (Aib) substitution to block DPP-4 N-terminal cleavage, and a fatty diacid chain that enables reversible albumin binding to slow renal clearance [9]. They differ in the length of that chain and the backbone they are built on.
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Backbone | GLP-1(7–37) analogue (~94% homology) | GIP-derived sequence optimized for dual activity |
| DPP-4 resistance | Aib at position 8 | Aib at position 2 |
| Acylation | C18 fatty diacid at Lys26 | C20 fatty diacid at Lys26 |
| Albumin binding | >99% | High-affinity, albumin-bound |
| Half-life | ~165–184 h (~7 days) | ~120 h (~5 days) |
| Route(s) | Subcutaneous weekly; oral daily (SNAC) | Subcutaneous weekly |
| Steady state | ~4–5 weeks | ~4 weeks |
| Escalation rationale | Gradual titration for GI tolerance | Gradual titration for GI tolerance |
A practical distinction: semaglutide is the only one of the two with an approved oral formulation (Rybelsus), made possible by co-formulation with the absorption enhancer SNAC. Tirzepatide is administered only by subcutaneous injection. In in vitro terms, both are supplied as lyophilized powder and studied under buffer and concentration conditions that do not reproduce the albumin-binding, distribution, and clearance environment of systemic administration — a point that applies equally to receptor-binding and cAMP assays for either compound.
4. Weight-Loss Data: STEP vs SURMOUNT
The most-searched question about these two compounds is which produces more weight reduction. The honest research answer is layered. In each compound's pivotal obesity trial, tirzepatide reported the larger mean reduction — but STEP 1 and SURMOUNT-1 were separate trials, enrolling different participants under different protocols and durations, so their headline percentages are not a controlled comparison.
Approximate mean percent body-weight change from baseline. Semaglutide value from STEP 1 (68 weeks, 2.4 mg) [2]; tirzepatide values from SURMOUNT-1 (72 weeks) [3]. Bars come from separate trials with different populations and durations and are shown for reference, not as a controlled head-to-head. Verify exact figures from source publications.
Two observations are worth drawing from the data. First, at tirzepatide's lowest dose (5 mg), the mean reduction in SURMOUNT-1 (~−15.0%) was broadly similar to semaglutide 2.4 mg in STEP 1 (~−14.9%); the separation grows at tirzepatide's higher doses. Second, both programs showed strong dose-response and high responder rates — in STEP 1, ~86% of semaglutide participants achieved ≥5% loss, while in SURMOUNT-1 ~90% of the 15 mg group did, with a notable ~56% reaching ≥20% [2][3].
| Metric | Semaglutide 2.4 mg (STEP 1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|
| Mean weight change | −14.9% | −20.9% |
| Placebo comparator | −2.4% | −3.1% |
| Trial duration | 68 weeks | 72 weeks |
| Population | Obesity, no T2D (n=1,961) | Obesity, no T2D (n=2,539) |
| ≥5% weight loss | ~86% | ~90% |
| ≥20% weight loss | — | ~56% |
5. The Only Head-to-Head Trial: SURPASS-2
Cross-trial comparisons are inherently unreliable, which makes SURPASS-2 the single most important dataset for anyone comparing these two compounds: it is the only published randomized trial in which semaglutide and tirzepatide were tested within the same study. Frías et al. (2021, NEJM) randomized adults with type 2 diabetes to tirzepatide 5, 10, or 15 mg or semaglutide 1 mg over 40 weeks [1].
| Outcome | Sema 1 mg | Tirz 5 mg | Tirz 10 mg | Tirz 15 mg |
|---|---|---|---|---|
| HbA1c change (pp) | −1.86 | −1.94 | −2.01 | −2.30 |
| Body-weight change | −5.7 kg | −7.8 kg | −9.3 kg | −11.2 kg |
| HbA1c <7.0% | 79% | 82% | 80% | 86% |
| HbA1c ≤6.5% | 56% | 63% | 69% | 75% |
In SURPASS-2, all three tirzepatide doses produced greater average HbA1c and body-weight reductions than semaglutide, with a dose-dependent pattern. This is the strongest evidence that tirzepatide's dual-receptor mechanism translates into greater average metabolic effect in a controlled setting.
The essential caveat — and the reason this trial does not fully settle the "which is stronger" question — is the comparator dose. SURPASS-2 used semaglutide 1 mg, the type 2 diabetes dose, not the higher 2.4 mg obesity dose used in the STEP program. No published head-to-head trial has yet compared tirzepatide against semaglutide 2.4 mg. Any comparison at the obesity dose therefore still rests on cross-trial inference.
6. Cardiovascular & Kidney Evidence
Weight and glucose numbers dominate search interest, but for the research and clinical literature the more consequential differentiator is outcome evidence — whether a compound has been shown in a dedicated, adequately powered trial to reduce hard endpoints like heart attack, stroke, or kidney-disease progression. Here the two compounds are at different stages of maturity.
Semaglutide has two landmark dedicated outcomes trials. SELECT (Lincoff et al., 2023, n=17,604) reported a 20% reduction in major adverse cardiovascular events in overweight/obese adults without diabetes (HR 0.80; 95% CI 0.72–0.90) [5]. FLOW (Perkovic et al., 2024) reported a 24% reduction in a composite kidney outcome in type 2 diabetes with chronic kidney disease (HR 0.76) [6]. Together these give semaglutide established cardiovascular and renal outcome data.
Tirzepatide's dedicated cardiovascular outcomes trial, SURPASS-CVOT, has now been published. In adults with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events, but did not demonstrate statistically significant superiority for the primary endpoint. This gives tirzepatide dedicated cardiovascular outcomes evidence — though it is an active-comparator (versus dulaglutide, itself a GLP-1 agonist) noninferiority result, a different kind of signal than semaglutide's placebo-controlled superiority. In short: semaglutide still has the clearer placebo-controlled cardiovascular outcome signal in obesity without diabetes (SELECT) plus dedicated renal data (FLOW), while tirzepatide now has its own dedicated cardiovascular outcomes trial.
7. Side Effects & Tolerability Compared
Because both compounds fully activate GLP-1R, their adverse-event profiles are closely related. In both the STEP and SURMOUNT programs, the most frequent adverse events were gastrointestinal — nausea, diarrhea, vomiting, and constipation — concentrated during the dose-escalation phase and predominantly mild to moderate and transient. Gradual titration is used with both to allow tolerance to develop.
Both also carry the same class-level contraindication derived from rodent carcinogenicity findings: they are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Human epidemiological data have not established a causal relationship between GLP-1 receptor agonism and medullary thyroid carcinoma, and long-term surveillance continues to accumulate for both compounds.
A frequently asked comparative question is whether tirzepatide is "harder to tolerate" because it is more potent. Head-to-head, SURPASS-2 did not show a dramatically different tolerability profile; the gastrointestinal event categories were similar in kind between the two arms, consistent with their shared GLP-1R mechanism. Individual tolerability varies, and this summary is not a substitute for professional medical assessment.
8. Brand Names: Ozempic / Wegovy vs Mounjaro / Zepbound
Much of the public search interest in these compounds uses brand names rather than the peptide names. For clarity, here is how the active peptides map to their approved branded products. Note that the research-grade material supplied by Wholesale Peps is unformulated compound for in vitro laboratory use only — it is not any of these finished medicines.
| Active peptide | Brand(s) | Indication | Maker |
|---|---|---|---|
| Semaglutide | Ozempic | Type 2 diabetes (SC) | Novo Nordisk |
| Semaglutide | Wegovy | Weight management (SC 2.4 mg) | Novo Nordisk |
| Semaglutide | Rybelsus | Type 2 diabetes (oral) | Novo Nordisk |
| Tirzepatide | Mounjaro | Type 2 diabetes (SC) | Eli Lilly |
| Tirzepatide | Zepbound | Weight management (SC) | Eli Lilly |
So "Ozempic vs Mounjaro" and "Wegovy vs Zepbound" are, at the molecular level, the same comparison as semaglutide vs tirzepatide — a GLP-1 monoagonist versus a GIP/GLP-1 dual agonist. The brand differences within each peptide (for example Ozempic vs Wegovy) reflect approved indication and dose, not a different active compound.
9. Limitations of This Comparison
Comparing two compounds studied in largely separate trial programs requires caution. The following limitations apply to essentially every "semaglutide vs tirzepatide" comparison, including this one.
Frequently Asked Questions
Common semaglutide vs tirzepatide questions, answered from the published research literature.
What is the difference between semaglutide and tirzepatide?+
Is tirzepatide stronger than semaglutide?+
Which produces more weight loss, semaglutide or tirzepatide?+
Is semaglutide the same as Ozempic and tirzepatide the same as Mounjaro?+
Do semaglutide and tirzepatide have the same side effects?+
Which has more cardiovascular and kidney outcome evidence?+
What happens to weight after stopping semaglutide or tirzepatide?+
References
- Friás JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
- Willard FS, Douros JD, Gabe MBN, et al. "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight. 2020;5(17):e140532. doi:10.1172/jci.insight.140532
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563
- Perkovic V, Tuttle KR, Rossing P, et al. "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes." New England Journal of Medicine. 2024;391(2):109–121. doi:10.1056/NEJMoa2403347
- Rubino DM, Greenway FL, Khalid U, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity." JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224
- Aronne LJ, Sattar N, Horn DB, et al. "Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)." JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
- Lau J, Bloch P, Schäffer L, et al. "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." Journal of Medicinal Chemistry. 2015;58(18):7370–7380. doi:10.1021/acs.jmedchem.5b00726
- Drucker DJ. "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1." Cell Metabolism. 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001